Cure Today

MDS Treatment Advances: Targeted Therapies and Anemia Management

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...
Monthly Prescribing Reference

Reblozyl Approved as First-Line Treatment for Anemia in Lower-Risk Myelodysplastic Syndromes

Credit: Getty Images. The approval was based on data from the pivotal phase 3 COMMANDS trial that compared luspatercept to epoetin alfa in 356 patients with anemia and lower-risk MDS. The Food and ...
The American Journal of Managed Care

Roxadustat Misses Mark as Anemia Treatment in Transfusion-Dependent, Lower-risk MDS

The phase 3 MATTERHORN trial examining roxadustat as an anemia treatment in patients with transfusion-dependent, lower-risk myelodysplastic syndrome did not meet its primary end point. The phase 3 ...
The American Journal of Managed Care

ESA Treatment Improves OS in Lower-Risk MDS

ESA treatment in lower-risk MDS patients is linked to improved overall survival and quality of life. Avoiding red blood cell transfusions is associated with significantly better health-related quality ...
Business Wire

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
Cure Today

Reblozyl May Be ‘The Standard of Care’ Now in Lower-Risk MDS, Anemia

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS. Reblozyl (luspatercept) has become the new standard ...
Business Wire

Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
NJBIZ

FDA grants expanded approval for Bristol Myers Squibb anemia therapy

The U.S. Food and Drug Administration has granted expanded approval of a therapy for anemia from Bristol Myers Squibb, the Princeton-based business announced Aug. 28. According to the ...
Healio

Luspatercept ‘a paradigm shift’ in transfusion-dependent myelodysplastic syndrome

Please provide your email address to receive an email when new articles are posted on . Significantly more patients who received luspatercept vs. epoetin alfa achieved the study’s primary endpoint of ...
Nasdaq

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion ...

SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of ...
Business Insider

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence; One Study Patient Achieved Hemoglobin Response Endpoint – – Safety Profile Consistent with Data Reported in Healthy ...
Seeking Alpha

FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)

SAN FRANCISCO, May 05, 2023 (GLOBE NEWSWIRE) -- FibroGen (FGEN), Inc. today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with ...